Todd Asset Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 16.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 282,442 shares of the company’s stock after acquiring an additional 40,131 shares during the quarter. AbbVie comprises 1.3% of Todd Asset Management LLC’s holdings, making the stock its 24th biggest position. Todd Asset Management LLC’s holdings in AbbVie were worth $71,074,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of ABBV. Journey Advisory Group LLC increased its position in shares of AbbVie by 0.4% during the second quarter. Journey Advisory Group LLC now owns 47,472 shares of the company’s stock worth $11,946,000 after purchasing an additional 181 shares in the last quarter. Aerodigm Wealth LLC purchased a new position in AbbVie during the 2nd quarter worth $225,000. Boomfish Wealth Group LLC increased its position in AbbVie by 5.3% during the 2nd quarter. Boomfish Wealth Group LLC now owns 1,443 shares of the company’s stock valued at $363,000 after buying an additional 72 shares in the last quarter. Strive Financial Group LLC raised its stake in AbbVie by 192.1% in the second quarter. Strive Financial Group LLC now owns 2,182 shares of the company’s stock valued at $549,000 after buying an additional 1,435 shares during the last quarter. Finally, Capital City Trust Co. FL boosted its holdings in AbbVie by 0.5% in the second quarter. Capital City Trust Co. FL now owns 34,427 shares of the company’s stock worth $8,663,000 after acquiring an additional 164 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ABBV has been the topic of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. UBS Group upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Guggenheim lifted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Morgan Stanley reiterated an “overweight” rating and set a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. Finally, HSBC reissued a “buy” rating and set a $300.00 price objective on shares of AbbVie in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.95.
AbbVie Stock Performance
Shares of ABBV opened at $265.62 on Friday. The business’s 50-day moving average is $248.48 and its two-hundred day moving average is $227.49. The company has a market capitalization of $469.29 billion, a P/E ratio of 75.03, a P/E/G ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.
AbbVie Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s payout ratio is presently 195.48%.
AbbVie News Summary
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
- Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
- Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
- Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
- Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
- Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale
Insider Buying and Selling
In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
